Quarterly Consolidated Statement Of Cash Flows

Modalis Therapeutics Corporation - Filing #7312187

Concept 2024-01-01 to
2024-06-30
As at
2024-06-30
As at
2023-12-31
2023-01-01 to
2023-06-30
As at
2023-06-30
As at
2022-12-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-780,340,000 JPY
-1,032,620,000 JPY
Depreciation
JPY
683,000 JPY
Impairment losses
188,000 JPY
37,146,000 JPY
Interest and dividend income
-8,000 JPY
-14,000 JPY
Interest expenses
2,057,000 JPY
2,212,000 JPY
Foreign exchange losses (gains)
-56,613,000 JPY
-37,317,000 JPY
Other, net
12,209,000 JPY
-66,009,000 JPY
Subtotal
-928,151,000 JPY
-975,925,000 JPY
Interest and dividends received
8,000 JPY
14,000 JPY
Interest paid
-2,057,000 JPY
-2,212,000 JPY
Income taxes paid
-1,210,000 JPY
-1,210,000 JPY
Net cash provided by (used in) operating activities
-931,410,000 JPY
-979,332,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-188,000 JPY
-37,830,000 JPY
Net cash provided by (used in) investing activities
-188,000 JPY
-37,830,000 JPY
Cash flows from financing activities
Other, net
JPY
-293,000 JPY
Net cash provided by (used in) financing activities
256,143,000 JPY
615,005,000 JPY
Effect of exchange rate change on cash and cash equivalents
70,299,000 JPY
60,387,000 JPY
Net increase (decrease) in cash and cash equivalents
-605,155,000 JPY
-341,771,000 JPY
Cash and cash equivalents
1,278,281,000 JPY
1,883,437,000 JPY
2,591,391,000 JPY
2,933,162,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.